Edward Chandy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Edward Chandy has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Catarina Veiga
Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom
3 shared publications - Giles Critchley
Department of Neurosurgery, University Hospitals Sussex NHS Foundation Trust, Brighton, UK
3 shared publications - Jamie R. McClelland
UCL, Ctr Med Image Comp, London, England
3 shared publications - Stephen David Robinson
Sussex Cancer Centre, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
3 shared publications - Ciaran Scott Hill
National Hospital for Neurology and Neurosurgery, Brain Tumour Service (Neuro-Oncology), London, UK
2 shared publications - Joseph Jacob
UCL Respiratory, University College London, London, UK
2 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 178 (2) , 41
Report of treatment intensity and survival outcomes in older patients with glioblastoma diagnosed according to WHO CNS 5 classification
Purpose: Glioblastoma is the most common primary brain cancer in adults, with half of cases diagnosed in patients aged ≥ 65 years. However, definitions of older adults vary, resulting in treatment variation between centres. This study aimed to report on the treatment intensity and survival outcomes in older patients with glioblastoma diagnosed according to WHO CNS 5 classification. Methods: We conducted a retrospective, multicentre cohort study (Histo-Mol GBM Collaborative) of consecutive patients with pathologically confirmed glioblastoma, IDH-wildtype diagnosed in 2021, according to the 2021 WHO CNS 5 classification, across 52 centres in the UK, Ireland, New Zealand, and Australia. Demographic, molecular, treatment, and survival data were analysed. Results: Of 1,857 patients, 863 (46.5%) were aged ≥ 65 years. Older patients had worse performance status, were more likely to have a biopsy, and received less intensive oncological therapy. Molecular testing was less comprehensive for older patients, but in those patients tested there was no difference with older age. Median overall survival declined with older age, with the steepest reduction in patients ≥ 70 years. Patients aged 65–69 derived comparable benefit from conventionally fractionated chemoradiation to adults aged < 65, whereas outcomes in those aged ≥ 70 were equivalent when treated with hypofractionated or conventionally fractionated chemoradiation. In multivariate analysis, oncological treatment intensity, completion of adjuvant therapy, and MGMT promoter methylation were independent predictors of survival. Conclusions: This international clinical dataset of adults diagnosed with glioblastoma since the introduction of the WHO CNS 5 criteria supports the use of conventionally fractionated chemoradiation in fit patients < 70, while hypofractionated regimens are appropriate for those ≥ 70. Surgical extent, treatment intensity, and MGMT methylation remain key determinants of survival in older patients with glioblastoma.
- 4 June 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 178 (2) , 41
Open AccessReport of treatment intensity and survival outcomes in older patients with glioblastoma diagnosed according to WHO CNS 5 classification
Purpose: Glioblastoma is the most common primary brain cancer in adults, with half of cases diagnosed in patients aged ≥ 65 years. However, definitions of older adults vary, resulting in treatment variation between centres. This study aimed to report on the treatment intensity and survival outcomes in older patients with glioblastoma diagnosed according to WHO CNS 5 classification. Methods: We conducted a retrospective, multicentre cohort study (Histo-Mol GBM Collaborative) of consecutive patients with pathologically confirmed glioblastoma, IDH-wildtype diagnosed in 2021, according to the 2021 WHO CNS 5 classification, across 52 centres in the UK, Ireland, New Zealand, and Australia. Demographic, molecular, treatment, and survival data were analysed. Results: Of 1,857 patients, 863 (46.5%) were aged ≥ 65 years. Older patients had worse performance status, were more likely to have a biopsy, and received less intensive oncological therapy. Molecular testing was less comprehensive for older patients, but in those patients tested there was no difference with older age. Median overall survival declined with older age, with the steepest reduction in patients ≥ 70 years. Patients aged 65–69 derived comparable benefit from conventionally fractionated chemoradiation to adults aged < 65, whereas outcomes in those aged ≥ 70 were equivalent when treated with hypofractionated or conventionally fractionated chemoradiation. In multivariate analysis, oncological treatment intensity, completion of adjuvant therapy, and MGMT promoter methylation were independent predictors of survival. Conclusions: This international clinical dataset of adults diagnosed with glioblastoma since the introduction of the WHO CNS 5 criteria supports the use of conventionally fractionated chemoradiation in fit patients < 70, while hypofractionated regimens are appropriate for those ≥ 70. Surgical extent, treatment intensity, and MGMT methylation remain key determinants of survival in older patients with glioblastoma.
- Open Access
- 8 January 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (2) , 157
Understanding the difference in symptoms and outcomes between glioblastoma patients diagnosed based on histological or molecular criteria: a retrospective cohort analysis from the Histo-Mol GBM collaborative
Purpose: Since the 2021 World Health Organisation (WHO) classification, glioblastoma could be diagnosed based on classical histological features (hGBM) or molecular criteria (mGBM). However, prior studies included patients who required reclassification as a mGBM, potentially biasing survival analyses. The Histo-Mol GBM collaborative performed an international multicentre retrospective real-world cohort study of glioblastoma patients diagnosed according to WHO CNS 5. Methods: We identified consecutive patients diagnosed in 2021 with IDH wildtype glioblastoma according to WHO CNS 5. Clinicopathological, treatment, and survival data were collected and compared between mGBM and hGBM. Results: 1828 patients diagnosed with glioblastoma were included. 75 mGBM patients (8.4% of tested patients) were identified, with no difference in age (median 61 vs 64, p = 0.057), gender ( p = 0.937), or proportion with performance status 0–1 (82.7% vs 68.3%, p = 0.052) compared to hGBM. mGBM patients had an extended interval from MRI to surgery (median 23 vs 14 days, p < 0.001) and more frequently underwent biopsy (69.3% vs 30.3%, p < 0.001), but equivalent proportions received oncological treatment (80.0% vs 78.7%, p = 0.784). Overall survival (OS) from surgery was not different ( p = 0.063). However, OS from initial MRI, stratified by surgical extent, demonstrated improved OS for mGBM patients (hazard ratio (HR) 0.56, 95% confidence interval (CI): 0.43–0.73). Propensity score matching identified improved survival following resection (HR 0.48, 95% CI: 0.24–0.95; median OS: 26.0 versus 14.0 months, p = 0.031) but not biopsy (HR 1.10, 95% CI: 0.71–1.72). Conclusion: In this large real-world cohort, mGBMs had longer OS than hGBMs following resection with implications for prognostication and clinical decision making.
- 8 January 2026
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 176 (2) , 157
Open AccessUnderstanding the difference in symptoms and outcomes between glioblastoma patients diagnosed based on histological or molecular criteria: a retrospective cohort analysis from the Histo-Mol GBM collaborative
Purpose: Since the 2021 World Health Organisation (WHO) classification, glioblastoma could be diagnosed based on classical histological features (hGBM) or molecular criteria (mGBM). However, prior studies included patients who required reclassification as a mGBM, potentially biasing survival analyses. The Histo-Mol GBM collaborative performed an international multicentre retrospective real-world cohort study of glioblastoma patients diagnosed according to WHO CNS 5. Methods: We identified consecutive patients diagnosed in 2021 with IDH wildtype glioblastoma according to WHO CNS 5. Clinicopathological, treatment, and survival data were collected and compared between mGBM and hGBM. Results: 1828 patients diagnosed with glioblastoma were included. 75 mGBM patients (8.4% of tested patients) were identified, with no difference in age (median 61 vs 64, p = 0.057), gender ( p = 0.937), or proportion with performance status 0–1 (82.7% vs 68.3%, p = 0.052) compared to hGBM. mGBM patients had an extended interval from MRI to surgery (median 23 vs 14 days, p < 0.001) and more frequently underwent biopsy (69.3% vs 30.3%, p < 0.001), but equivalent proportions received oncological treatment (80.0% vs 78.7%, p = 0.784). Overall survival (OS) from surgery was not different ( p = 0.063). However, OS from initial MRI, stratified by surgical extent, demonstrated improved OS for mGBM patients (hazard ratio (HR) 0.56, 95% confidence interval (CI): 0.43–0.73). Propensity score matching identified improved survival following resection (HR 0.48, 95% CI: 0.24–0.95; median OS: 26.0 versus 14.0 months, p = 0.031) but not biopsy (HR 1.10, 95% CI: 0.71–1.72). Conclusion: In this large real-world cohort, mGBMs had longer OS than hGBMs following resection with implications for prognostication and clinical decision making.
- Open Access
- 29 January 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 26 (6) , 1138-1151
Glioblastoma and radiotherapy: A multicenter AI study for Survival Predictions from MRI (GRASP study)
The aim was to predict survival of glioblastoma at 8 months after radiotherapy (a period allowing for completing a typical course of adjuvant temozolomide), by applying deep learning to the first brain MRI after radiotherapy completion. Retrospective and prospective data were collected from 206 consecutive glioblastoma, isocitrate dehydrogenase -wildtype patients diagnosed between March 2014 and February 2022 across 11 UK centers. Models were trained on 158 retrospective patients from 3 centers. Holdout test sets were retrospective (n = 19; internal validation), and prospective (n = 29; external validation from 8 distinct centers). Neural network branches for T2-weighted and contrast-enhanced T1-weighted inputs were concatenated to predict survival. A nonimaging branch (demographics/MGMT/treatment data) was also combined with the imaging model. We investigated the influence of individual MR sequences; nonimaging features; and weighted dense blocks pretrained for abnormality detection. The imaging model outperformed the nonimaging model in all test sets (area under the receiver-operating characteristic curve, AUC P = .038) and performed similarly to a combined imaging/nonimaging model (P > .05). Imaging, nonimaging, and combined models applied to amalgamated test sets gave AUCs of 0.93, 0.79, and 0.91. Initializing the imaging model with pretrained weights from 10 000s of brain MRIs improved performance considerably (amalgamated test sets without pretraining 0.64; P = .003). A deep learning model using MRI images after radiotherapy reliably and accurately determined survival of glioblastoma. The model serves as a prognostic biomarker identifying patients who will not survive beyond a typical course of adjuvant temozolomide, thereby stratifying patients into those who might require early second-line or clinical trial treatment.
- 29 January 2024
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 26 (6) , 1138-1151
Open AccessGlioblastoma and radiotherapy: A multicenter AI study for Survival Predictions from MRI (GRASP study)
The aim was to predict survival of glioblastoma at 8 months after radiotherapy (a period allowing for completing a typical course of adjuvant temozolomide), by applying deep learning to the first brain MRI after radiotherapy completion. Retrospective and prospective data were collected from 206 consecutive glioblastoma, isocitrate dehydrogenase -wildtype patients diagnosed between March 2014 and February 2022 across 11 UK centers. Models were trained on 158 retrospective patients from 3 centers. Holdout test sets were retrospective (n = 19; internal validation), and prospective (n = 29; external validation from 8 distinct centers). Neural network branches for T2-weighted and contrast-enhanced T1-weighted inputs were concatenated to predict survival. A nonimaging branch (demographics/MGMT/treatment data) was also combined with the imaging model. We investigated the influence of individual MR sequences; nonimaging features; and weighted dense blocks pretrained for abnormality detection. The imaging model outperformed the nonimaging model in all test sets (area under the receiver-operating characteristic curve, AUC P = .038) and performed similarly to a combined imaging/nonimaging model (P > .05). Imaging, nonimaging, and combined models applied to amalgamated test sets gave AUCs of 0.93, 0.79, and 0.91. Initializing the imaging model with pretrained weights from 10 000s of brain MRIs improved performance considerably (amalgamated test sets without pretraining 0.64; P = .003). A deep learning model using MRI images after radiotherapy reliably and accurately determined survival of glioblastoma. The model serves as a prognostic biomarker identifying patients who will not survive beyond a typical course of adjuvant temozolomide, thereby stratifying patients into those who might require early second-line or clinical trial treatment.
- Open Access
- 16 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , iii20-iii21
FOCAL MANAGEMENT OF BRAIN METASTASES IN SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW
Small cell lung cancer (SCLC) brain metastases (BM) are common at both presentation and relapse. Historically, BM are managed with whole brain radiotherapy (WBRT) +/- chemotherapy. However, WBRT is associated with significant cognitive impairment, and so interest in the focal management of BM (encompassing stereotactic radiosurgery (SRS) and surgery) is increasing. We systematically reviewed the current literature regarding focal BM management. A systematic literature search of PubMed, Embase, and CENTRAL databases and clinicaltrials.gov was conducted to obtain published articles, abstracts, and ongoing studies regarding focal management of SCLC BM. Exclusion criteria included publication before 2005 and publication in a non-English language. Additional papers were added by reviewing citations of relevant papers. Following initial review of 15,420 records, we identified 67 articles eligible for inclusion. 24 were published before 2015 and 44 published 2015-2023. 8 related to surgical BM treatment: case studies (n=6), retrospective cohort studies (n=2). 60 articles were identified regarding SRS: abstracts (n=13), case studies (n=5), retrospective cohort studies (n=14), retrospective case series (n=20), prospective trials (n=8). These papers have been further divided by topic: upfront SRS (n=23), salvage SRS (n=19) and WBRT with SRS boost (n=3). There are several ongoing trials (n=8) investigating outcomes in SRS for SCLC BM, both alone and when compared with WBRT. Focal treatments for SCLC BM are being used more frequently. However, randomised trial evidence for their safety and effectiveness are still pending.
- 16 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , iii20-iii21
Open AccessFOCAL MANAGEMENT OF BRAIN METASTASES IN SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW
Small cell lung cancer (SCLC) brain metastases (BM) are common at both presentation and relapse. Historically, BM are managed with whole brain radiotherapy (WBRT) +/- chemotherapy. However, WBRT is associated with significant cognitive impairment, and so interest in the focal management of BM (encompassing stereotactic radiosurgery (SRS) and surgery) is increasing. We systematically reviewed the current literature regarding focal BM management. A systematic literature search of PubMed, Embase, and CENTRAL databases and clinicaltrials.gov was conducted to obtain published articles, abstracts, and ongoing studies regarding focal management of SCLC BM. Exclusion criteria included publication before 2005 and publication in a non-English language. Additional papers were added by reviewing citations of relevant papers. Following initial review of 15,420 records, we identified 67 articles eligible for inclusion. 24 were published before 2015 and 44 published 2015-2023. 8 related to surgical BM treatment: case studies (n=6), retrospective cohort studies (n=2). 60 articles were identified regarding SRS: abstracts (n=13), case studies (n=5), retrospective cohort studies (n=14), retrospective case series (n=20), prospective trials (n=8). These papers have been further divided by topic: upfront SRS (n=23), salvage SRS (n=19) and WBRT with SRS boost (n=3). There are several ongoing trials (n=8) investigating outcomes in SRS for SCLC BM, both alone and when compared with WBRT. Focal treatments for SCLC BM are being used more frequently. However, randomised trial evidence for their safety and effectiveness are still pending.
- Open Access
A Novel and Automated Approach to Classify Radiation Induced Lung Tissue Damage on CT Scans
Radiation-induced lung damage (RILD) is a common side effect of radiotherapy (RT). The ability to automatically segment, classify, and quantify different types of lung parenchymal change is essential to uncover underlying patterns of RILD and their evolution over time. A RILD dedicated tissue classification system was developed to describe lung parenchymal tissue changes on a voxel-wise level. The classification system was automated for segmentation of five lung tissue classes on computed tomography (CT) scans that described incrementally increasing tissue density, ranging from normal lung (Class 1) to consolidation (Class 5). For ground truth data generation, we employed a two-stage data annotation approach, akin to active learning. Manual segmentation was used to train a stage one auto-segmentation method. These results were manually refined and used to train the stage two auto-segmentation algorithm. The stage two auto-segmentation algorithm was an ensemble of six 2D Unets using different loss functions and numbers of input channels. The development dataset used in this study consisted of 40 cases, each with a pre-radiotherapy, 3-, 6-, 12-, and 24-month follow-up CT scans (n = 200 CT scans). The method was assessed on a hold-out test dataset of 6 cases (n = 30 CT scans). The global Dice score coefficients (DSC) achieved for each tissue class were: Class (1) 99% and 98%, Class (2) 71% and 44%, Class (3) 56% and 26%, Class (4) 79% and 47%, and Class (5) 96% and 92%, for development and test subsets, respectively. The lowest values for the test subsets were caused by imaging artefacts or reflected subgroups that occurred infrequently and with smaller overall parenchymal volumes. We performed qualitative evaluation on the test dataset presenting manual and auto-segmentation to a blinded independent radiologist to rate them as ‘acceptable’, ‘minor disagreement’ or ‘major disagreement’. The auto-segmentation ratings were similar to the manual segmentation, both having approximately 90% of cases rated as acceptable. The proposed framework for auto-segmentation of different lung tissue classes produces acceptable results in the majority of cases and has the potential to facilitate future large studies of RILD.
Open AccessA Novel and Automated Approach to Classify Radiation Induced Lung Tissue Damage on CT Scans
Radiation-induced lung damage (RILD) is a common side effect of radiotherapy (RT). The ability to automatically segment, classify, and quantify different types of lung parenchymal change is essential to uncover underlying patterns of RILD and their evolution over time. A RILD dedicated tissue classification system was developed to describe lung parenchymal tissue changes on a voxel-wise level. The classification system was automated for segmentation of five lung tissue classes on computed tomography (CT) scans that described incrementally increasing tissue density, ranging from normal lung (Class 1) to consolidation (Class 5). For ground truth data generation, we employed a two-stage data annotation approach, akin to active learning. Manual segmentation was used to train a stage one auto-segmentation method. These results were manually refined and used to train the stage two auto-segmentation algorithm. The stage two auto-segmentation algorithm was an ensemble of six 2D Unets using different loss functions and numbers of input channels. The development dataset used in this study consisted of 40 cases, each with a pre-radiotherapy, 3-, 6-, 12-, and 24-month follow-up CT scans (n = 200 CT scans). The method was assessed on a hold-out test dataset of 6 cases (n = 30 CT scans). The global Dice score coefficients (DSC) achieved for each tissue class were: Class (1) 99% and 98%, Class (2) 71% and 44%, Class (3) 56% and 26%, Class (4) 79% and 47%, and Class (5) 96% and 92%, for development and test subsets, respectively. The lowest values for the test subsets were caused by imaging artefacts or reflected subgroups that occurred infrequently and with smaller overall parenchymal volumes. We performed qualitative evaluation on the test dataset presenting manual and auto-segmentation to a blinded independent radiologist to rate them as ‘acceptable’, ‘minor disagreement’ or ‘major disagreement’. The auto-segmentation ratings were similar to the manual segmentation, both having approximately 90% of cases rated as acceptable. The proposed framework for auto-segmentation of different lung tissue classes produces acceptable results in the majority of cases and has the potential to facilitate future large studies of RILD.
- Open Access
- 27 August 2021
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 66 (17) , 175020
A multichannel feature-based approach for longitudinal lung CT registration in the presence of radiation induced lung damage
Quantifying parenchymal tissue changes in the lungs is imperative in furthering the study of radiation induced lung damage (RILD). Registering lung images from different time-points is a key step of this process. Traditional intensity-based registration approaches fail this task due to the considerable anatomical changes that occur between timepoints. This work proposes a novel method to successfully register longitudinal pre- and post-radiotherapy (RT) lung computed tomography (CT) scans that exhibit large changes due to RILD, by extracting consistent anatomical features from CT (lung boundaries, main airways, vessels) and using these features to optimise the registrations. Pre-RT and 12 month post-RT CT pairs from fifteen lung cancer patients were used for this study, all with varying degrees of RILD, ranging from mild parenchymal change to extensive consolidation and collapse. For each CT, signed distance transforms from segmentations of the lungs and main airways were generated, and the Frangi vesselness map was calculated. These were concatenated into multi-channel images and diffeomorphic multichannel registration was performed for each image pair using NiftyReg. Traditional intensity-based registrations were also performed for comparison purposes. For the evaluation, the pre- and post-registration landmark distance was calculated for all patients, using an average of 44 manually identified landmark pairs per patient. The mean (standard deviation) distance for all datasets decreased from 15.95 (8.09) mm pre-registration to 4.56 (5.70) mm post-registration, compared to 7.90 (8.97) mm for the intensity-based registrations. Qualitative improvements in image alignment were observed for all patient datasets. For four representative subjects, registrations were performed for three additional follow-up timepoints up to 48 months post-RT and similar accuracy was achieved. We have demonstrated that our novel multichannel registration method can successfully align longitudinal scans from RILD patients in the presence of large anatomical changes such as consolidation and atelectasis, outperforming the traditional registration approach both quantitatively and through thorough visual inspection.
- 27 August 2021
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 66 (17) , 175020
Open AccessA multichannel feature-based approach for longitudinal lung CT registration in the presence of radiation induced lung damage
Quantifying parenchymal tissue changes in the lungs is imperative in furthering the study of radiation induced lung damage (RILD). Registering lung images from different time-points is a key step of this process. Traditional intensity-based registration approaches fail this task due to the considerable anatomical changes that occur between timepoints. This work proposes a novel method to successfully register longitudinal pre- and post-radiotherapy (RT) lung computed tomography (CT) scans that exhibit large changes due to RILD, by extracting consistent anatomical features from CT (lung boundaries, main airways, vessels) and using these features to optimise the registrations. Pre-RT and 12 month post-RT CT pairs from fifteen lung cancer patients were used for this study, all with varying degrees of RILD, ranging from mild parenchymal change to extensive consolidation and collapse. For each CT, signed distance transforms from segmentations of the lungs and main airways were generated, and the Frangi vesselness map was calculated. These were concatenated into multi-channel images and diffeomorphic multichannel registration was performed for each image pair using NiftyReg. Traditional intensity-based registrations were also performed for comparison purposes. For the evaluation, the pre- and post-registration landmark distance was calculated for all patients, using an average of 44 manually identified landmark pairs per patient. The mean (standard deviation) distance for all datasets decreased from 15.95 (8.09) mm pre-registration to 4.56 (5.70) mm post-registration, compared to 7.90 (8.97) mm for the intensity-based registrations. Qualitative improvements in image alignment were observed for all patient datasets. For four representative subjects, registrations were performed for three additional follow-up timepoints up to 48 months post-RT and similar accuracy was achieved. We have demonstrated that our novel multichannel registration method can successfully align longitudinal scans from RILD patients in the presence of large anatomical changes such as consolidation and atelectasis, outperforming the traditional registration approach both quantitatively and through thorough visual inspection.
- Open Access
- 4 May 2021
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 66 (10) , 105005
Atlas construction and spatial normalisation to facilitate radiation-induced late effects research in childhood cancer
Reducing radiation-induced side effects is one of the most important challenges in paediatric cancer treatment. Recently, there has been growing interest in using spatial normalisation to enable voxel-based analysis of radiation-induced toxicities in a variety of patient groups. The need to consider three-dimensional distribution of doses, rather than dose-volume histograms, is desirable but not yet explored in paediatric populations. In this paper, we investigate the feasibility of atlas construction and spatial normalisation in paediatric radiotherapy. We used planning computed tomography (CT) scans from twenty paediatric patients historically treated with craniospinal irradiation to generate a template CT that is suitable for spatial normalisation. This childhood cancer population representative template was constructed using groupwise image registration. An independent set of 53 subjects from a variety of childhood malignancies was then used to assess the quality of the propagation of new subjects to this common reference space using deformable image registration (i.e. spatial normalisation). The method was evaluated in terms of overall image similarity metrics, contour similarity and preservation of dose-volume properties. After spatial normalisation, we report a dice similarity coefficient of 0.95 ± 0.05, 0.85 ± 0.04, 0.96 ± 0.01, 0.91 ± 0.03, 0.83 ± 0.06 and 0.65 ± 0.16 for brain and spinal canal, ocular globes, lungs, liver, kidneys and bladder. We then demonstrated the potential advantages of an atlas-based approach to study the risk of second malignant neoplasms after radiotherapy. Our findings indicate satisfactory mapping between a heterogeneous group of patients and the template CT. The poorest performance was for organs in the abdominal and pelvic region, likely due to respiratory and physiological motion and to the highly deformable nature of abdominal organs. More specialised algorithms should be explored in the future to improve mapping in these regions. This study is the first step toward voxel-based analysis in radiation-induced toxicities following paediatric radiotherapy.
- 4 May 2021
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 66 (10) , 105005
Open AccessAtlas construction and spatial normalisation to facilitate radiation-induced late effects research in childhood cancer
Reducing radiation-induced side effects is one of the most important challenges in paediatric cancer treatment. Recently, there has been growing interest in using spatial normalisation to enable voxel-based analysis of radiation-induced toxicities in a variety of patient groups. The need to consider three-dimensional distribution of doses, rather than dose-volume histograms, is desirable but not yet explored in paediatric populations. In this paper, we investigate the feasibility of atlas construction and spatial normalisation in paediatric radiotherapy. We used planning computed tomography (CT) scans from twenty paediatric patients historically treated with craniospinal irradiation to generate a template CT that is suitable for spatial normalisation. This childhood cancer population representative template was constructed using groupwise image registration. An independent set of 53 subjects from a variety of childhood malignancies was then used to assess the quality of the propagation of new subjects to this common reference space using deformable image registration (i.e. spatial normalisation). The method was evaluated in terms of overall image similarity metrics, contour similarity and preservation of dose-volume properties. After spatial normalisation, we report a dice similarity coefficient of 0.95 ± 0.05, 0.85 ± 0.04, 0.96 ± 0.01, 0.91 ± 0.03, 0.83 ± 0.06 and 0.65 ± 0.16 for brain and spinal canal, ocular globes, lungs, liver, kidneys and bladder. We then demonstrated the potential advantages of an atlas-based approach to study the risk of second malignant neoplasms after radiotherapy. Our findings indicate satisfactory mapping between a heterogeneous group of patients and the template CT. The poorest performance was for organs in the abdominal and pelvic region, likely due to respiratory and physiological motion and to the highly deformable nature of abdominal organs. More specialised algorithms should be explored in the future to improve mapping in these regions. This study is the first step toward voxel-based analysis in radiation-induced toxicities following paediatric radiotherapy.
- Open Access
- 1 July 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 148, 89-96
Investigation of the evolution of radiation-induced lung damage using serial CT imaging and pulmonary function tests
- 1 July 2020
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 148, 89-96
Open AccessInvestigation of the evolution of radiation-induced lung damage using serial CT imaging and pulmonary function tests
- Open Access
- 1 May 2020
- Published by Elsevier in Clinical Oncology
- Vol. 32 (5) , 316-326
Hypofractionated Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Tumours in Children and Young Adults
- 1 May 2020
- Published by Elsevier in Clinical Oncology
- Vol. 32 (5) , 316-326
Open AccessHypofractionated Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Tumours in Children and Young Adults
- 1 September 2019
- Published by Elsevier in Clinical Oncology
- Vol. 31 (9) , 670-671
Carbon and Cancer